Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M19,017Revenue (TTM) $M1,661Net Margin (%)-13.2Altman Z-Score5.0
Enterprise Value $M18,895EPS (TTM) $-0.9Operating Margin %-5.0Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.4Pre-tax Margin (%)-9.9Higher ROA y-yY
Price/Book18.610-y EBITDA Growth Rate %--Quick Ratio2.0Cash flow > EarningsY
Price/Sales11.25-y EBITDA Growth Rate %--Current Ratio2.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-8.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-22.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M248ROIC % (ttm)-9.1Gross Margin Increase y-yN

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXJoel Greenblatt 2016-09-30 Reduce-0.04%$85 - $102.83
($94.5)
$ 76.67-19%Reduce -38.60%66,716
VRTXGeorge Soros 2016-09-30 Sold Out -0.02%$85 - $102.83
($94.5)
$ 76.67-19%Sold Out0
VRTXKen Fisher 2016-09-30 Add$85 - $102.83
($94.5)
$ 76.67-19%Add 1.10%5,168
VRTXJoel Greenblatt 2016-06-30 Add0.1%$79.15 - $96.09
($86.3)
$ 76.67-11%Add 2053.31%108,656
VRTXVanguard Health Care Fund 2016-06-30 Add0.04%$79.15 - $96.09
($86.36)
$ 76.67-11%Add 1.95%12,914,741
VRTXJohn Paulson 2016-06-30 Sold Out -0.04%$79.15 - $96.09
($86.3)
$ 76.67-11%Sold Out0
VRTXLeucadia National 2016-06-30 Sold Out -0.04%$79.15 - $96.09
($86.3)
$ 76.67-11%Sold Out0
VRTXGeorge Soros 2016-06-30 Buy 0.02%$79.15 - $96.09
($86.3)
$ 76.67-11%New holding6,300
VRTXKen Fisher 2016-06-30 Reduce$79.15 - $96.09
($86.3)
$ 76.67-11%Reduce -0.83%5,112
VRTXVanguard Health Care Fund 2016-03-31 Add0.5%$78.4 - $125.83
($91.01)
$ 76.67-16%Add 28.91%12,668,241
VRTXLeucadia National 2016-03-31 Buy 0.04%$78.4 - $125.83
($91.01)
$ 76.67-16%New holding3,300
VRTXJoel Greenblatt 2016-03-31 Reduce-0.01%$78.4 - $125.83
($91.01)
$ 76.67-16%Reduce -57.21%5,046
VRTXJohn Paulson 2016-03-31 Add0.01%$78.4 - $125.83
($91.01)
$ 76.67-16%Add 32.54%61,500
VRTXKen Fisher 2016-03-31 Reduce$78.4 - $125.83
($91.01)
$ 76.67-16%Reduce -7.00%5,155
VRTXVanguard Health Care Fund 2015-12-31 Add0.1%$109.03 - $133.26
($121.16)
$ 76.67-37%Add 4.34%9,827,411
VRTXJohn Paulson 2015-12-31 Buy 0.04%$109.03 - $133.26
($121.16)
$ 76.67-37%New holding46,400
VRTXJoel Greenblatt 2015-12-31 Buy 0.02%$109.03 - $133.26
($121.16)
$ 76.67-37%New holding11,793
VRTXKen Fisher 2015-12-31 Add$109.03 - $133.26
($120.93)
$ 76.67-37%Add 12.48%5,543
VRTXVanguard Health Care Fund 2015-09-30 Reduce-0.03%$98.5 - $141.48
($128.47)
$ 76.67-40%Reduce -1.21%9,418,411
VRTXKen Fisher 2015-09-30 Add$98.5 - $141.48
($128.47)
$ 76.67-40%Add 12.56%4,928
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOGER JOSHUA SDirector 2016-12-07Sell6,500$75.152.02view
BOGER JOSHUA SDirector 2016-11-30Sell6,500$83.48-8.16view
BOGER JOSHUA SDirector 2016-11-23Sell6,500$86.47-11.33view
BOGER JOSHUA SDirector 2016-11-16Sell6,500$91.55-16.25view
Sachdev AmitEVP, Policy, Access & Value 2016-11-15Sell116$93.36-17.88view
Silva Paul MSVP & Corp Controller 2016-11-15Sell1$94.14-18.56view
Silva Paul MSVP & Corp Controller 2016-11-10Sell5,062$90.98-15.73view
BOGER JOSHUA SDirector 2016-11-09Sell6,500$90.98-15.73view
Arbuckle Stuart AEVP\Chief Commercial Officer 2016-11-09Sell1,208$90-14.81view
BOGER JOSHUA SDirector 2016-11-02Sell6,500$77.75-1.39view

Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Testing of Treatment for Cystic Fibrosis Patients Begins Nov 29 2016 
    Edward Owens Top 2nd Quarter Investments Aug 03 2016 
    Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
    Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
    Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
    Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
    Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 
    Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 

    More From Other Websites
    ETFs with exposure to Vertex Pharmaceuticals, Inc. : December 2, 2016 Dec 02 2016
    VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Change in Directors or Principal Officers Dec 02 2016
    Is State Street Corp (STT) Going to Burn These Hedge Funds? Dec 01 2016
    Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VRTX-US :... Dec 01 2016
    The Biggest Loser: Vertex Pharmaceuticals Drops 4.7% Nov 30 2016
    Testing of Treatment for Cystic Fibrosis Patients Begins Nov 29 2016
    More Base Building Ahead for Vertex Pharmaceuticals Nov 29 2016
    Top-performing Mass. biotech Corbus extends study of promising drug Nov 29 2016
    The Market In 5 Minutes: OPEC, Tiffany's And More Theranos Trouble Nov 29 2016
    Nivalis (NVLS) Cystic Fibrosis Study Misses Primary Endpoint Nov 29 2016
    Is Vertex Pharmaceuticals Incorporated (VRTX) Going to Burn These Hedge Funds? Nov 25 2016
    Zacks.com featured highlights: Allegheny Technologies, salesforce.com, United States Steel, Vertex... Nov 22 2016
    Amgen, Biogen, Celgene Eye M&A In Trump's 'Pro-Biotech' World Nov 21 2016
    Baker to life science, tech firms: Hire more high school interns Nov 21 2016
    Recent IPO Airgain Flies To New High After Strong Earnings Nov 14 2016
    Norwood's Corbus regains title as state's top-performing biotech on drug study results Nov 14 2016
    Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VRTX-US :... Nov 11 2016
    5 Health Care Stocks Set to Bounce Nov 10 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)